Novo Nordisk CEO spars with lawmakers over Ozempic, Wegovy prices

The CEO of Novo Nordisk faced pointed questions about the cost of Ozempic and Wegovy on Capitol Hill Tuesday, as lawmakers pressed the Danish pharmaceutical giant to cut the prices of its blockbuster diabetes and obesity medications.

Previous post Buy this REIT’s stock to make money on the rapid aging of America’s population
Next post US spot Ethereum ETFs see largest daily outflows Since July